Johnson & Johnson has proposed a settlement worth up to $5.5 billion to resolve thousands of lawsuits claiming its talc-based baby powder products caused cancer. The deal addresses decades of litigation that has shadowed the healthcare giant's reputation and balance sheet.
Plaintiffs have alleged that J&J's talc products, including its iconic Johnson's Baby Powder, contained asbestos contamination and caused mesothelioma and ovarian cancer. The company has consistently denied these claims, stating that its talc is safe and asbestos-free. However, the mounting legal costs and reputational damage have pushed the firm toward settlement.
This settlement represents one of the largest product liability payouts in recent corporate history. It follows J&J's decision to discontinue talc baby powder sales in North America in 2020, a move that signaled the company's acknowledgment of market concerns, even as it maintained the product's safety.
The proposal still requires court approval and agreement from claimants. Some plaintiffs may reject the settlement if they believe their individual cases warrant larger awards. The company has faced bankruptcy proceedings related to talc claims previously, making this settlement a significant step toward closure.
J&J's move reflects broader industry trends around legacy product liabilities and corporate accountability. The talc litigation has paralleled other major settlements, including those over opioids and PFOA contamination. For investors, the payout reduces future legal uncertainty but impacts earnings. For public health advocates, the settlement provides compensation to alleged victims while the underlying scientific debate over talc's carcinogenicity remains contested in some quarters.